Drug and cell delivery for cardiac regeneration

Advanced Drug Delivery Reviews

Volumn 84, Issue , 2015, Pages 85-106

  Hastings, Conn L ^a,b   Roche, Ellen T ^c,d   Ruiz Hernandez, Eduardo ^a,b   Schenke Layland, Katja ^e,f,g   Walsh, Conor J ^c,d   Duffy, Garry P ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomaterials; Cell therapy; Drug delivery; Growth factor; Heart failure; Medical device; Myocardial infarction; Regenerative medicine

Indexed keywords

BIOLOGICAL MATERIALS; BIOMATERIALS; BIOMEDICAL EQUIPMENT; CARDIOLOGY; DRUG DELIVERY; HEART;

CELL THERAPY; GROWTH FACTOR; HEART FAILURE; MEDICAL DEVICES; MYOCARDIAL INFARCTION; REGENERATIVE MEDICINE;

DRUG THERAPY;

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; ALPHA CYCLODEXTRIN; ANTAGOMIR; CHITOSAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; MACROGOL; MICRORNA; MODIFIED RNA; MOLECULAR SCAFFOLD; NANOPARTICLE; NEU DIFFERENTIATION FACTOR; PERFORMED POROUS SCAFFOLD; POLYCAPROLACTONE; PROSTACYCLIN; PROSTAGLANDIN E2 DERIVATIVE; PYRVINIUM EMBONATE; RETROVIRUS VECTOR; RNA; SCATTER FACTOR; SMALL MOLECULE TRANSPORT AGENT; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT1 PROTEIN; BIOLOGICAL FACTOR;

ANGINA PECTORIS; ANTICOAGULATION; ARTIFICIAL EMBOLISM; BONE MARROW CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIAC REGENERATION; CARDIAC STEM CELL; CARDIOPOIETIC STEM CELL; CATHETERIZATION; CELL POPULATION; CELL SURVIVAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; EXTRACELLULAR MATRIX; FGF 2 GENE; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HUMAN; HYDROGEL; HYPOTENSION; IMMUNOGENICITY; MESENCHYMAL STEM CELL; MINIMALLY INVASIVE PROCEDURE; MYOBLAST; NANOENCAPSULATION; NONHUMAN; NUCLEAR REPROGRAMMING; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN TARGETING; PURIFICATION; REVIEW; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; TRANSLATIONAL RESEARCH; VIRAL GENE DELIVERY SYSTEM; XENOTRANSPLANTATION; DRUG EFFECTS; HEART; PHYSIOLOGY; PROCEDURES; REGENERATION;

BIOLOGICAL FACTORS; DRUG DELIVERY SYSTEMS; HEART; HUMANS; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 84929132593     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.08.006     Document Type: Review

References (263)

1. Burchfield J.S., Xie M., Hill J.a. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 2013, 128:388-400. 10.1161/CIRCULATIONAHA.113.001878.
2. Mukherjee S., Venugopal J.R., Ravichandran R., Ramakrishna S., Raghunath M. Multimodal biomaterial strategies for regeneration of infarcted myocardium. J. Mater. Chem. 2010, 20:8819. 10.1039/c0jm00805b.
3. Templin C., Lüscher T.F., Landmesser U. Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy - current status and future developments. Int. J. Dev. Biol. 2011, 55:407-417. 10.1387/ijdb.103219ct.
4. Seif-Naraghi S.B., Singelyn J.M., Salvatore M.a, Osborn K.G., Wang J.J., Sampat U., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci. Transl. Med. 2013, 5:173ra25. 10.1126/scitranslmed.3005503.
5. McMurray J.J.V., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012, 33:1787-1847. 10.1093/eurheartj/ehs104.
6. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245. 10.1161/CIR.0b013e31828124ad.
7. Venugopal J.R., Prabhakaran M.P., Mukherjee S., Ravichandran R., Dan K., Ramakrishna S. Biomaterial strategies for alleviation of myocardial infarction. J. R. Soc. Interface 2012, 9:1-19. 10.1098/rsif.2011.0301.
8. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148. 10.1016/S0140-6736(04)16626-9.
9. Giugliano R.P., Braunwald E. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation 2003, 108:2828-2830. 10.1161/01.CIR.0000106684.71725.98.
10. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705. 10.1038/35070587.
11. Orlic D., Kajstura J., Chimenti S., Limana F., Jakoniuk I., Quaini F., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10344-10349. 10.1073/pnas.181177898.
12. Kudo M., Wang Y., Wani M.A., Xu M., Ayub A., Ashraf M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. J. Mol. Cell. Cardiol. 2003, 35:1113-1119. 10.1016/S0022-2828(03)00211-6.
13. Tomita S., Li R.K., Weisel R.D., Mickle D.A., Kim E.J., Sakai T., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999, 100:II247-II256.
14. Tang J., Xie Q., Pan G., Wang J., Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur. J. Cardiothorac. Surg. 2006, 30:353-361. 10.1016/j.ejcts.2006.02.070.
15. Kajstura J., Rota M., Whang B., Cascapera S., Hosoda T., Bearzi C., et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 2005, 96:127-137. 10.1161/01.RES.0000151843.79801.60.
16. Rota M., Kajstura J., Hosoda T., Bearzi C., Vitale S., Esposito G., et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17783-17788. 10.1073/pnas.0706406104.
17. Zhang S., Guo J., Zhang P., Liu Y., Jia Z., Ma K., et al. Long-term effects of bone marrow mononuclear cell transplantation on left ventricular function and remodeling in rats. Life Sci. 2004, 74:2853-2864. 10.1016/j.lfs.2003.10.035.
18. Kamihata H., Matsubara H., Nishiue T., Fujiyama S., Tsutsumi Y., Ozono R., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001, 104:1046-1052. 10.1161/hc3501.093817.
19. Tang Y.L., Zhao Q., Zhang Y.C., Cheng L., Liu M., Shi J., et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul. Pept. 2004, 117:3-10. 10.1016/j.regpep.2003.09.005.
20. Silva G.V., Litovsky S., Assad J.A.R., Sousa A.L.S., Martin B.J., Vela D., et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005, 111:150-156. 10.1161/01.CIR.0000151812.86142.45.
21. Zhang D.-Z., Gail L.-Y., Liu H.-W., Jin Q., Hunag J., Zhu X. Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction. Chin. Med. J. 2007, 120:300-307.
22. Murry C.E., Soonpaa M.H., Reinecke H., Nakajima H., Nakajima H.O., Rubart M., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004, 428:664-668. 10.1038/nature02446.
23. Assmus B., Schächinger V., Teupe C., Britten M., Lehmann R., Dobert N., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017. 10.1161/01.CIR.0000043246.74879.CD.
24. Schächinger V., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., Hölschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 2006, 355:1210-1221. 10.1056/NEJMoa060186.
25. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294. 10.1161/CIRCULATIONAHA.105.575118.
26. Huikuri H.V., Kervinen K., Niemela M., Ylitalo K., Saily M., Koistinen P., et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur. Heart J. 2008, 2723-2732.
27. Leistner D.M., Fischer-Rasokat U., Honold J., Seeger F.H., Schächinger V., Lehmann R., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin. Res. Cardiol. 2011, 100:925-934. 10.1007/s00392-011-0327-y.
28. Meyer G.P., Wollert K.C., Lotz J., Pirr J., Rager U., Lippolt P., et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 2009, 30:2978-2984. 10.1093/eurheartj/ehp374.
29. Lunde K., Solheim S., Aakhus S., Arnesen H., Abdelnoor M., Egeland T., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 2006, 355:1199-1209.
30. Roncalli J., Mouquet F., Piot C., Trochu J.-N., Le Corvoisier P., Neuder Y., et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur. Heart J. 2011, 32:1748-1757. 10.1093/eurheartj/ehq455.
31. Janssens S., Dubois C., Bogaert J., Theunissen K., Deroose C., Desmet W., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006, 367:113-121. 10.1016/S0140-6736(05)67861-0.
32. Hirsch A., Nijveldt R., van der Vleuten P.a, Tijssen J.G.P., van der Giessen W.J., Tio R.a, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur. Heart J. 2011, 32:1736-1747.
33. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2277-2286. 10.1016/j.jacc.2009.06.055.
34. Traverse J.H., Henry T.D., Pepine C.J., Willerson J.T., Zhao D.X.M., Ellis S.G., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012, 308:2380-2389. 10.1001/jama.2012.28726.
35. Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., Zhao D.X.M., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306:2110-2119. 10.1001/jama.2011.1670.
36. Perin E.C., Willerson J.T., Pepine C.J., Henry T.D., Ellis S.G., Zhao D.X.M., et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307:1717-1726. 10.1001/jama.2012.418.
37. Assmus B., Honold J., Schächinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 2006, 355:1222-1232. 10.1056/NEJMoa051779.
38. Behfar A., Yamada S., Crespo-Diaz R., Nesbitt J.J., Rowe L.A., Perez-Terzic C., et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 2010, 56:721-734. 10.1016/j.jacc.2010.03.066.
39. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20:661-669. 10.1096/fj.05-5211com.
40. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103:1204-1219. 10.1161/CIRCRESAHA.108.176826.
41. Malliaras K., Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br. Med. Bull. 2011, 161-185.
42. Yoon Y., Wecker A., Heyd L., Park J.-S., Tkebuchava T., Kusano K., et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 2005, 115:326-338. 10.1172/JCI22326.
43. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379. 10.1001/jama.2012.25321.
44. Valina C., Pinkernell K., Song Y.-H., Bai X., Sadat S., Campeau R.J., et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur. Heart J. 2007, 28:2667-2677. 10.1093/eurheartj/ehm426.
45. Houtgraaf J.H., den Dekker W.K., van Dalen B.M., Springeling T., de Jong R., van Geuns R.J., et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2012, 59:539-540. 10.1016/j.jacc.2011.09.065.
46. Perin E.C., Sanchez P.L., Ruiz R.S., Perez-Cano R., Lasso J., Alonso-Farto J.C., et al. First in man transendocardial injection of autologous adipose-derived stem cells in patients with non revascularizable ischemic myocardium (PRECISE) (Abstract). Circulation 2010, A17966.
47. Qayyum A.A., Haack-Sørensen M., Mathiasen A.B., Jørgensen E., Ekblond A., Kastrup J. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen. Med. 2012, 7:421-428. 10.2217/rme.12.17.
48. Mangi A.A., Noiseux N., Kong D., He H., Rezvani M., Ingwall J.S., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 2003, 9:1195-1201. 10.1038/nm912.
49. Losordo D.W., Henry T.D., Davidson C., Sup Lee J., Costa M.A., Bass T., et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ. Res. 2011, 109:428-436. 10.1161/CIRCRESAHA.111.245993.
50. Losordo D.W., Schatz R.A., White C.J., Udelson J.E., Veereshwarayya V., Durgin M., et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007, 115:3165-3172. 10.1161/CIRCULATIONAHA.106.687376.
51. van Ramshorst J., Bax J.J., Beeres S.L.M.A., Dibbets-Schneider P., Roes S.D., Stokkel M.P.M., et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009, 301:1997-2004. 10.1001/jama.2009.685.
52. + cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013, 128:S42-S49. 10.1161/CIRCULATIONAHA.112.000230.
53. Chiu R.C., Zibaitis A., Kao R.L. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. 1995, 60:12-18.
54. Taylor D.A., Atkins B.Z., Hungspreugs P., Jones T.R., Reedy M.C., Hutcheson K.A., et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 1998, 4:929-933.
55. Pouzet B., Ghostine S., Vilquin J.T., Garcin I., Scorsin M., Hagège A.A., et al. Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors?. Circulation 2001, 104:I223-I228.
56. Jain M., DerSimonian H., Brenner D.A., Ngoy S., Teller P., Edge A.S., et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001, 103:1920-1927.
57. Rajnoch C., Chachques J.C., Berrebi A., Bruneval P., Benoit M.O., Carpentier A. Cellular therapy reverses myocardial dysfunction. J. Thorac. Cardiovasc. Surg. 2001, 121:871-878. 10.1067/mtc.2001.112937.
58. Murry C.E., Wiseman R.W., Schwartz S.M., Hauschka S.D. Skeletal myoblast transplantation for repair of myocardial necrosis. J. Clin. Invest. 1996, 98:2512-2523. 10.1172/JCI119070.
59. Yoon P.D., Kao R.L., Magovern G.J. Myocardial regeneration. Transplanting satellite cells into damaged myocardium. Tex. Heart Inst. J. 1995, 22:119-125.
60. Ghostine S., Carrion C., César L., Souza G., Richard P., Vilquin J., et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002, 106:I131-I136. 10.1161/01.cir.0000032889.55215.f1.
61. Menasché P., Hagège A.a, Vilquin J.-T., Desnos M., Abergel E., Pouzet B., et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 2003, 41:1078-1083.
62. Menasché P., Alfieri O., Janssens S., McKenna W., Reichenspurner H., Trinquart L., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008, 117:1189-1200. 10.1161/CIRCULATIONAHA.107.734103.
63. Reinecke H., Poppa V., Murry C.E. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell. Cardiol. 2002, 34:241-249. 10.1006/jmcc.2001.1507.
64. Reinecke H., Murry C.E. Transmural replacement of myocardium after skeletal myoblast grafting into the heart. Too much of a good thing?. Cardiovasc. Pathol. 2000, 9:337-344.
65. Oshima H., Payne T.R., Urish K.L., Sakai T., Ling Y., Gharaibeh B., et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol. Ther. 2005, 12:1130-1141. 10.1016/j.ymthe.2005.07.686.
66. Choi Y., Neef K., Treskes P., Kumar S., Liakopoulos O., Stamm C., et al. Cardiogenic progenitor cells derived from skeletal muscle - a promising autologous cell source for cardiac cell therapy. Thorac. Cardiovasc. Surg. 2011, 59:V143. 10.1055/s-0030-1269167.
67. Haider H.K., Lei Y., Ashraf M. MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr. Opin. Mol. Ther. 2008, 10:611-621.
68. Smits P.C., van Geuns R.-J.M., Poldermans D., Bountioukos M., Onderwater E.E.M., Lee C.H., et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol. 2003, 42:2063-2069.
69. Steendijk P., Smits P.C., Valgimigli M., van der Giessen W.J., Onderwater E.E., Serruys P.W. Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops. Nat. Clin. Pract. Cardiovasc. Med. 2006, S1:S94-S100.
70. Ince H., Petzsch M., Rehders T.C., Chatterjee T., Nienaber C.A. Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J. Endovasc. Ther. 2004, 11:695-704. 10.1583/04-1386R.1.
71. Smits P.C., Nienaber C., Colombo A., Ince H., Carlino M., Theuns D.A.M.J., et al. Myocardial repair by percutaneous cell transplantation of autologous skeletal myoblast as a stand alone procedure in post myocardial infarction chronic heart failure patients. EuroIntervention 2006, 1:417-424.
72. Matsuura K., Nagai T., Nishigaki N., Oyama T., Nishi J., Wada H., et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J. Biol. Chem. 2004, 279:11384-11391. 10.1074/jbc.M310822200.
73. Bearzi C., Rota M., Hosoda T., Tillmanns J., Nascimbene A., De Angelis A., et al. Human cardiac stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14068-14073. 10.1073/pnas.0706760104.
74. Messina E., De Angelis L., Frati G., Morrone S., Chimenti S., Fiordaliso F., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 2004, 95:911-921. 10.1161/01.RES.0000147315.71699.51.
75. Mazhari R., Hare J.M. Advances in cell-based therapy for structural heart disease. Prog. Cardiovasc. Dis. 2007, 49:387-395. 10.1016/j.pcad.2007.03.004.
76. Cesselli D., Beltrami A.P., D'Aurizio F., Marcon P., Bergamin N., Toffoletto B., et al. Effects of age and heart failure on human cardiac stem cell function. Am. J. Pathol. 2011, 179:349-366. 10.1016/j.ajpath.2011.03.036.
77. Ellison G.M., Vicinanza C., Smith A.J., Aquila I., Leone A., Waring C.D., et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013, 154:827-842. 10.1016/j.cell.2013.07.039.
78. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
79. Chugh A.R., Beache G.M., Loughran J.H., Mewton N., Elmore J.B., Kajstura J., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012, 126:S54-S64. 10.1161/CIRCULATIONAHA.112.092627.
80. + cells minimally contribute cardiomyocytes to the heart. Nature 2014, 509:337-341. 10.1038/nature13309.
81. + precursors support postinfarction myogenesis in the neonatal, but not adult, heart. PNAS 2012, 109:13380-13385. 10.1073/pnas.1208114109/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1208114109.
82. Hesse M., Fleischmann B.K., Kotlikoff M.I. Concise review: the role of C-kit expressing cells in heart repair at the neonatal and adult stage. Stem Cells 2014, 32:1701-1712.
83. Makkar R.R., Smith R.R., Cheng K., Malliaras K., Thomson L.E., Berman D., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012, 379:895-904.
84. Chimenti I., Smith R.R., Li T.-S., Gerstenblith G., Messina E., Giacomello A., et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 2010, 106:971-980. 10.1161/CIRCRESAHA.109.210682.
85. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740. 10.1161/01.CIR.0000068356.38592.68.
86. Laflamme M.a, Chen K.Y., Naumova A.V., Muskheli V., Fugate J.a, Dupras S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25:1015-1024. 10.1038/nbt1327.
87. Behfar A., Perez-Terzic C., Faustino R.S., Arrell D.K., Hodgson D.M., Yamada S., et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J. Exp. Med. 2007, 204:405-420. 10.1084/jem.20061916.
88. Behfar A., Terzic A. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3(Suppl. 1):S78-S82. 10.1038/ncpcardio0429.
89. Bartunek J., Behfar A., Dolatabadi D., Vanderheyden M., Ostojic M., Dens J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 2013, 61:2329-2338. 10.1016/j.jacc.2013.02.071.
90. Sullivan K.E., Quinn K.P., Tang K.M., Georgakoudi I., Black L.D. Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells. Stem Cell Res. Ther. 2014, 5:14. 10.1186/scrt403.
91. Singelyn J.M., Christman K.L. Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J. Cardiovasc. Transl. Res. 2010, 3:478-486. 10.1007/s12265-010-9202-x.
92. Laflamme M.a, Murry C.E. Heart regeneration. Nature 2011, 473:326-335. 10.1038/nature10147.
93. Ashraf M., Dimmeler S., Robey T.E., Saiget M.K., Reinecke H., Murry C.E. Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell. Cardiol. 2008, 45:567-581.
94. Wang H., Liu Z., Li D., Guo X., Kasper F.K., Duan C., et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. J. Cell. Mol. Med. 2012, 16:1310-1320. 10.1111/j.1582-4934.2011.01409.x.
95. Hamdi H., Furuta A., Bellamy V., Bel A., Puymirat E., Peyrard S., et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann. Thorac. Surg. 2009, 87:1196-1203. 10.1016/j.athoracsur.2008.12.074.
96. Smith R.R., Marbán E., Marbán L. Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel. Biomatter 2013, 3.
97. Qian L., Shim W., Gu Y., Shirhan M., Lim K.P., Tan L.P., et al. Hemodynamic contribution of stem cell scaffolding in acute injured myocardium. Tissue Eng. A 2012, 18:1652-1663. 10.1089/ten.TEA.2011.0591.
98. Liu Z., Wang H., Wang Y., Lin Q., Yao A., Cao F., et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials 2012, 33:3093-3106. 10.1016/j.biomaterials.2011.12.044.
99. Wang H., Shi J., Wang Y., Yin Y., Wang L., Liu J., et al. Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction. Biomaterials 2014, 35:3986-3998. 10.1016/j.biomaterials.2014.01.021.
100. Wang T., Jiang X.-J., Tang Q.-Z., Li X.-Y., Lin T., Wu D.-Q., et al. Bone marrow stem cells implantation with α-cyclodextrin/MPEG-PCL-MPEG hydrogel improves cardiac function after myocardial infarction. Acta Biomater. 2009, 5:2939-2944.
101. Yost M.J., Baicu C.F., Stonerock C.E., Goodwin R.L., Price R.L., Davis J.M., et al. A novel tubular scaffold for cardiovascular tissue engineering. Tissue Eng. 2004, 10:273-284. 10.1089/107632704322791916.
102. Thornton A.J., Alsberg E., Hill E.E., Mooney D.J. Shape retaining injectable hydrogels for minimally invasive bulking. J. Urol. 2004, 172:763-768. 10.1097/01.ju.0000130466.84214.f7.
103. Bencherif S.a, Sands R.W., Bhatta D., Arany P., Verbeke C.S., Edwards D.a, et al. Injectable preformed scaffolds with shape-memory properties. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:19590-19595. 10.1073/pnas.1211516109.
104. Khalil S., Sun W. Bioprinting endothelial cells with alginate for 3D tissue constructs. J. Biomech. Eng. 2009, 131:111002. 10.1115/1.3128729.
105. Zhang G., Hu Q., Braunlin E.A., Suggs L.J., Zhang J. Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng. A 2008, 14:1025-1036. 10.1089/ten.tea.2007.0289.
106. Yu J., Du K.T., Fang Q., Gu Y., Mihardja S.S., Sievers R.E., et al. The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials 2010, 31:7012-7020.
107. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J. Am. Coll. Cardiol. 2004, 44:654-660. 10.1016/j.jacc.2004.04.040.
108. Habib M., Shapira-Schweitzer K., Caspi O., Gepstein A., Arbel G., Aronson D., et al. A combined cell therapy and in-situ tissue-engineering approach for myocardial repair. Biomaterials 2011, 32:7514-7523.
109. Martens T.P., Godier A.F.G., Parks J.J., Wan L.Q., Koeckert M.S., Eng G.M., et al. Percutaneous cell delivery into the heart using hydrogels polymerizing in situ. Cell Transplant. 2009, 18:297-304. 10.3727/096368909788534915.
110. Lu W.-N., Lü S.-H., Wang H.-B., Li D.-X., Duan C.-M., Liu Z.-Q., et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng. A 2009, 15:1437-1447. 10.1089/ten.tea.2008.0143.
111. Leor J., Aboulafia-Etzion S., Dar A., Shapiro L., Barbash I.M., Battler A., et al. Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium?. Circulation 2000, 102:III-56-III-61. 10.1161/01.CIR.102.suppl_3.III-56.
112. Dar A., Shachar M., Leor J., Cohen S. Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffolds. Biotechnol. Bioeng. 2002, 80:305-312. 10.1002/bit.10372.
113. Simpson D., Liu H., Fan T.-H.M., Nerem R., Dudley S.C. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells 2007, 25:2350-2357. 10.1634/stemcells.2007-0132.
114. Simpson D.L., Boyd N.L., Kaushal S., Stice S.L., Dudley S.C. Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair. Biotechnol. Bioeng. 2012, 109:274-283. 10.1002/bit.23301.
115. Humphries M.J. Identification of an alternatively spliced site in human plasma fibronectin that mediates cell type-specific adhesion. J. Cell Biol. 1986, 103:2637-2647. 10.1083/jcb.103.6.2637.
116. Griffith L.G., Lopina S. Microdistribution of substratum-bound ligands affects cell function: hepatocyte spreading on PEO-tethered galactose. Biomaterials 1998, 19:979-986. 10.1016/S0142-9612(97)00185-3.
117. Rowley J.A., Madlambayan G., Mooney D.J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20:45-53.
118. Tiwari A., Salacinski H.J., Punshon G., Hamilton G., Seifalian A.M. Development of a hybrid cardiovascular graft using a tissue engineering approach. FASEB J. 2002, 16:791-796. 10.1096/fj.01-0826com.
119. Pratt A.B., Weber F.E., Schmoekel H.G., Müller R., Hubbell J.A. Synthetic extracellular matrices for in situ tissue engineering. Biotechnol. Bioeng. 2004, 86:27-36. 10.1002/bit.10897.
120. Eschenhagen T., Zimmermann W.H. Engineering myocardial tissue. Circ. Res. 2005, 97:1220-1231. 10.1161/01.RES.0000196562.73231.7d.
121. Akhyari P., Fedak P.W.M., Weisel R.D., Lee T.-Y.J., Verma S., Mickle D.A.G., et al. Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation 2002, 106:I137-I142.
122. Eschenhagen T., Didié M., Münzel F., Schubert P., Schneiderbanger K., Zimmermann W.-H. 3D engineered heart tissue for replacement therapy. Basic Res. Cardiol. 2002, 97(Suppl. 1):I146-I152.
123. Eschenhagen T., Didié M., Heubach J., Ravens U., Zimmermann W.-H. Cardiac tissue engineering. Transpl. Immunol. 2002, 9:315-321. 10.1016/S0966-3274(02)00011-4.
124. Kofidis T., Lenz A., Boublik J., Akhyari P., Wachsmann B., Stahl K.M., et al. Bioartificial grafts for transmural myocardial restoration: a new cardiovascular tissue culture concept. Eur. J. Cardiothorac. Surg. 2003, 24:906-911.
125. Kofidis T., Akhyari P., Wachsmann B., Boublik J., Mueller-Stahl K., Leyh R., et al. A novel bioartificial myocardial tissue and its prospective use in cardiac surgery. Eur. J. Cardiothorac. Surg. 2002, 22:238-243.
126. Kofidis T., Akhyari P., Boublik J., Theodorou P., Martin U., Ruhparwar A., et al. In vitro engineering of heart muscle: artificial myocardial tissue. J. Thorac. Cardiovasc. Surg. 2002, 124:63-69.
127. Zimmermann W.-H., Melnychenko I., Wasmeier G., Didié M., Naito H., Nixdorff U., et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 2006, 12:452-458. 10.1038/nm1394.
128. Zimmermann W., Didié M., Wasmeier G.H., Nixdorff U., Melnychenko I., Boy O., et al. Cardiac Grafting of Engineered Heart Tissue in Syngenic Rats 2002, 10.1161/01.cir.0000032876.55215.10.
129. Kai D., Wang Q.-L., Wang H.-J., Prabhakaran M.P., Zhang Y., Tan Y.-Z., et al. Stem cell-loaded nanofibrous patch promotes the regeneration of infarcted myocardium with functional improvement in rat model. Acta Biomater. 2014, 10.1016/j.actbio.2014.02.030.
130. Soler-Botija C., Bagó J.R., Bayes-Genis A. A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration. Ann. N. Y. Acad. Sci. 2012, 1254:57-65. 10.1111/j.1749-6632.2012.06519.x.
131. Nunes S.S., Miklas J.W., Liu J., Aschar-Sobbi R., Xiao Y., Zhang B., et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 2013, 10:781-787. 10.1038/nmeth.2524.
132. Korf-Klingebiel M., Kempf T., Sauer T., Brinkmann E., Fischer P., Meyer G.P., et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur. Heart J. 2008, 29:2851-2858. 10.1093/eurheartj/ehn456.
133. Russo V., Young S., Hamilton A., Amsden B.G., Flynn L.E. Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury. Biomaterials 2014, 35:3956-3974. 10.1016/j.biomaterials.2014.01.075.
134. Jackson B.M., Gorman J.H., Moainie S.L., Guy T.S., Narula N., Narula J., et al. Extension of borderzone myocardium in postinfarction dilated cardiomyopathy. J. Am. Coll. Cardiol. 2002, 40:1160-1167.
135. discussion 1168-71.
136. Gorman R.C., Jackson B.M., Gorman J.H. The potential role of ventricular compressive therapy. Surg. Clin. N. Am. 2004, 84:45-59.
137. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100:999-1008.
138. Jones R.H., Velazquez E.J., Michler R.E., Sopko G., Oh J.K., O'Connor C.M., et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J. Med. 2009, 360:1705-1717.
139. Dor V., Di Donato M., Sabatier M., Montiglio F., Civaio F. Left ventricular reconstruction by endoventricular circular patch plasty repair: a 17-year experience. Semin. Thorac. Cardiovasc. Surg. 2001, 13:435-437.
140. Batista R.J., Verde J., Nery P., Bocchino L., Takeshita N., Bhayana J.N., et al. Partial left ventriculectomy to treat end-stage heart disease. Ann. Thorac. Surg. 1997, 64:634-638. 10.1016/S0003-4975(97)00779-0.
141. Mann D.L., Acker M.A., Jessup M., Sabbah H.N., Starling R.C., Kubo S.H. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann. Thorac. Surg. 2007, 84:1226-1235. 10.1016/j.athoracsur.2007.03.095.
142. Chaudhry P.A., Mishima T., Sharov V.G., Hawkins J., Alferness C., Paone G., et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann. Thorac. Surg. 2000, 70:1275-1280.
143. Magovern J.A. Experimental and clinical studies with the Paracor cardiac restraint device. Semin. Thorac. Cardiovasc. Surg. 2005, 17:364-368. 10.1053/j.semtcvs.2005.09.006.
144. Grossi E.A., Patel N., Woo Y.J., Goldberg J.D., Schwartz C.F., Subramanian V., et al. Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J. Am. Coll. Cardiol. 2010, 56:1984-1993. 10.1016/j.jacc.2010.06.051.
145. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006, 114:2627-2635. 10.1161/CIRCULATIONAHA.106.657270.
146. Serpooshan V., Zhao M., Metzler S.A., Wei K., Shah P.B., Wang A., et al. The effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular function post myocardial infarction. Biomaterials 2013, 34:9048-9055. 10.1016/j.biomaterials.2013.08.017.
147. Ifkovits J.L., Tous E., Minakawa M., Morita M., Robb J.D., Koomalsingh K.J., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11507-11512. 10.1073/pnas.1004097107.
148. Christman K.L., Fok H.H., Sievers R.E., Fang Q., Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004, 10:403-409. 10.1089/107632704323061762.
149. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117:1388-1396. 10.1161/CIRCULATIONAHA.107.727420.
150. Leor J., Tuvia S., Guetta V., Manczur F., Castel D., Willenz U., et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J. Am. Coll. Cardiol. 2009, 54:1014-1023. 10.1016/j.jacc.2009.06.010.
151. Tsur-Gang O., Ruvinov E., Landa N., Holbova R., Feinberg M.S., Leor J., et al. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 2009, 30:189-195. 10.1016/j.biomaterials.2008.09.018.
152. Yu J., Gu Y., Du K.T., Mihardja S., Sievers R.E., Lee R.J. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials 2009, 30:751-756. 10.1016/j.biomaterials.2008.09.059.
153. Dai W., Wold L.E., Dow J.S., Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J. Am. Coll. Cardiol. 2005, 46:714-719. 10.1016/j.jacc.2005.04.056.
154. Yoon S.J., Fang Y.H., Lim C.H., Kim B.S., Son H.S., Park Y., et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. J. Biomed. Mater. Res. B Appl. Biomater. 2009, 91:163-171. 10.1002/jbm.b.31386.
155. Kofidis T., de Bruin J.L., Hoyt G., Lebl D.R., Tanaka M., Yamane T., et al. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J. Thorac. Cardiovasc. Surg. 2004, 128:571-578. 10.1016/j.jtcvs.2004.05.021.
156. Dobner S., Bezuidenhout D., Govender P., Zilla P., Davies N. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J. Card. Fail. 2009, 15:629-636. 10.1016/j.cardfail.2009.03.003.
157. Jiang X.-J., Wang T., Li X.-Y., Wu D.-Q., Zheng Z.-B., Zhang J.-F., et al. Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. J. Biomed. Mater. Res. A 2009, 90:472-477. 10.1002/jbm.a.32118.
158. Wang T., Jiang X.-J., Lin T., Ren S., Li X.-Y., Zhang X.-Z., et al. The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. Biomaterials 2009, 30:4161-4167. 10.1016/j.biomaterials.2009.04.033.
159. Fujimoto K.L., Ma Z., Nelson D.M., Hashizume R., Guan J., Tobita K., et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. Biomaterials 2009, 30:4357-4368. 10.1016/j.biomaterials.2009.04.055.
160. Wang T., Wu D.-Q., Jiang X.-J., Zhang X.-Z., Li X.-Y., Zhang J.-F., et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur. J. Heart Fail. 2009, 11:14-19. 10.1093/eurjhf/hfn009.
161. Mukherjee R., Zavadzkas J.A., Saunders S.M., McLean J.E., Jeffords L.B., Beck C., et al. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann. Thorac. Surg. 2008, 86:1268-1276. 10.1016/j.athoracsur.2008.04.107.
162. Morita M., Eckert C.E., Matsuzaki K., Noma M., Ryan L.P., Burdick J.A., et al. Modification of infarct material properties limits adverse ventricular remodeling. Ann. Thorac. Surg. 2011, 92:617-624. 10.1016/j.athoracsur.2011.04.051.
163. Ryan L.P., Matsuzaki K., Noma M., Jackson B.M., Eperjesi T.J., Plappert T.J., et al. Dermal filler injection: a novel approach for limiting infarct expansion. Ann. Thorac. Surg. 2009, 87:148-155. 10.1016/j.athoracsur.2008.09.028.
164. Fujimoto K.L., Tobita K., Merryman W.D., Guan J., Momoi N., Stolz D.B., et al. An elastic, biodegradable cardiac patch induces contractile smooth muscle and improves cardiac remodeling and function in subacute myocardial infarction. J. Am. Coll. Cardiol. 2007, 49:2292-2300. 10.1016/j.jacc.2007.02.050.
165. Lee L.C., Wall S.T., Klepach D., Ge L., Zhang Z., Lee R.J., et al. Algisyl-LVR™ with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart. Int. J. Cardiol. 2013, 168:2022-2028. 10.1016/j.ijcard.2013.01.003.
166. Tous E., Purcell B., Ifkovits J.L., Burdick J.a Injectable acellular hydrogels for cardiac repair. J. Cardiovasc. Transl. Res. 2011, 4:528-542.
167. Huang N.F., Yu J., Sievers R., Li S., Lee R.J. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng. 2005, 11:1860-1866. 10.1089/ten.2005.11.1860.
168. Yu J., Christman K.L., Chin E., Sievers R.E., Saeed M., Lee R.J. Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2009, 137:180-187. 10.1016/j.jtcvs.2008.08.036.
169. Nelson D.M., Ma Z., Fujimoto K.L., Hashizume R., Wagner W.R. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges. Acta Biomater. 2011, 7:1-15. 10.1016/j.actbio.2010.06.039.
170. Doppler S.a, Deutsch M.-A., Lange R., Krane M. Cardiac regeneration: current therapies - future concepts. J. Thorac. Dis. 2013, 5:683-697. 10.3978/j.issn.2072-1439.2013.08.71.
171. Radisic M., Park H., Shing H., Consi T., Schoen F.J., Langer R., et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18129-18134. 10.1073/pnas.0407817101.
172. Vunjak-Novakovic G., Lui K.O., Tandon N., Chien K.R. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu. Rev. Biomed. Eng. 2011, 13:245-267. 10.1146/annurev-bioeng-071910-124701.
173. Jung D.W., Williams D.R. Reawakening atlas: chemical approaches to repair or replace dysfunctional musculature. ACS Chem. Biol. 2012, 7:1773-1790. 10.1021/cb3003368.
174. Hsueh Y.C., Wu J.M., Yu C.K., Wu K.K., Hsieh P.C. Prostaglandin E2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol. Med. 2014, 6:496-503. 10.1002/emmm.201303687.
175. Ishimaru K., Miyagawa S., Fukushima S., Saito A., Sakai Y., Ueno T., et al. Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart. J. Thorac. Cardiovasc. Surg. 2013, 146:1516-1525. (S0022-5223(13)00200-6). 10.1016/j.jtcvs.2013.02.045.
176. Nakamura K., Sata M., Iwata H., Sakai Y., Hirata Y., Kugiyama K., et al. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin. Sci. 2007, 112:607-616. (CS20060301). 10.1042/CS20060301.
177. Murakoshi M., Saiki K., Urayama K., Sato T.N. PLoS One 2013, 8:e79374. (PONE-D-13-30084). 10.1371/journal.pone.0079374.
178. Saraswati S., Alfaro M.P., Thorne C.A., Atkinson J., Lee E., Young P.P. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010, 5:e15521. 10.1371/journal.pone.0015521.
179. Sanada F., Kim J., Czarna A., Chan N.Y., Signore S., Ogorek B., et al. c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy. Circ. Res. 2014, 114:41-55. (CIRCRESAHA.114.302500). 10.1161/CIRCRESAHA.114.302500.
180. Zaruba M.M., Theiss H.D., Vallaster M., Mehl U., Brunner S., David R., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323. (S1934-5909(09)00068-X). 10.1016/j.stem.2009.02.013.
181. Theiss H.D., Vallaster M., Rischpler C., Krieg L., Zaruba M.M., Brunner S., et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res. 2011, 7:244-255. (S1873-5061(11)00062-6). 10.1016/j.scr.2011.05.003.
182. Theiss H.D., Brenner C., Engelmann M.G., Zaruba M.M., Huber B., Henschel V., et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) - rationale, design and first interim analysis. Int. J. Cardiol. 2010, 145:282-284. (S0167-5273(09)01501-0). 10.1016/j.ijcard.2009.09.555.
183. Kormann M.S., Hasenpusch G., Aneja M.K., Nica G., Flemmer A.W., Herber-Jonat S., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011, 29:154-157. (nbt.1733). 10.1038/nbt.1733.
184. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630. S1934-5909(10)00434-0. 10.1016/j.stem.2010.08.012.
185. Armeanu S., Pelisek J., Krausz E., Fuchs A., Groth D., Curth R., et al. Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol. Ther. 2000, 1:366-375. (S1525-0016(00)90053-4). 10.1006/mthe.2000.0053.
186. Parelkar S.S., Letteri R., Chan-Seng D., Zolochevska O., Ellis J., Figueiredo M., et al. Polymer-peptide delivery platforms: effect of oligopeptide orientation on polymer-based DNA delivery. Biomacromolecules 2014, 10.1021/bm401878p.
187. Zangi L., Lui K.O., von Gise A., Ma Q., Ebina W., Ptaszek L.M., et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 2013, 31:898-907. (nbt.2682). 10.1038/nbt.2682.
188. Fiedler J., Thum T. MicroRNAs in myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2013, 33:201-205. (33/2/201 [pii]). 10.1161/ATVBAHA.112.300137.
189. Eulalio A., Mano M., Dal Ferro M., Zentilin L., Sinagra G., Zacchigna S., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492:376-381. (nature11739 [pii]). 10.1038/nature11739.
190. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713. ((80-), 1174381 [pii]). 10.1126/science.1174381.
191. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110. (nature11919 [pii]). 10.1038/nature11919.
192. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122:S124-S131. (122/11_suppl_1/S124 [pii]). 10.1161/CIRCULATIONAHA.109.928424.
193. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Invest. 2007, 117:3615-3622. 10.1172/JCI33483.
194. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J. Control. Release 2013, 172:962-974. (S0168-3659(13)00803-1 [pii]). 10.1016/j.jconrel.2013.09.015.
195. Muthiah M., Park I.K., Cho C.S. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin. Drug Deliv. 2013, 10:1259-1273. 10.1517/17425247.2013.798640.
196. Chistiakov D.A., Sobenin I.A., Orekhov A.N. Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv. 2012, 19:392-405. 10.3109/10717544.2012.738436.
197. Gill S.L., O'Neill H., McCoy R.J., Logeswaran S., O'Brien F., Stanton A., et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol. Health Care 2014, (P4657P428T65H353 [pii]). 10.3233/THC-130772.
198. Monaghan M., Browne S., Schenke-Layland K., Pandit A. A collagen-based scaffold delivering exogenous microRNA-29B to modulate extracellular matrix remodeling. Mol. Ther. 2014, 22:786-796. (mt2013288 [pii]). 10.1038/mt.2013.288.
199. Li Y., Fan L., Liu S., Liu W., Zhang H., Zhou T., et al. The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a. Biomaterials 2013, 34:5048-5058. (S0142-9612(13)00362-1 [pii]). 10.1016/j.biomaterials.2013.03.052.
200. Wang H., Cao N., Spencer C.I., Nie B., Ma T., Xu T., et al. Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4. Cell Rep. 2014, 6:951-960. 10.1016/j.celrep.2014.01.038.
201. Ieda M., Fu J.-D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386. 10.1016/j.cell.2010.07.002.
202. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598. 10.1038/nature11044.
203. Song K., Nam Y.-J., Luo X., Qi X., Tan W., Huang G.N., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485:599-604. 10.1038/nature11139.
204. Jayawardena T.M., Egemnazarov B., Finch E.a, Zhang L., Payne J.A., Pandya K., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ. Res. 2012, 110:1465-1473.
205. Yi B.A., Mummery C.L., Chien K.R. Direct cardiomyocyte reprogramming: a new direction for cardiovascular regenerative medicine. Cold Spring Harb. Perspect. Med. 2013, 3:a014050. 10.1101/cshperspect.a014050.
206. Plowright A.T., Engkvist O., Gill A., Knerr L., Wang Q.D. Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. Angew. Chem. Int. Ed. Engl. 2014, 10.1002/anie.201307034.
207. Pavo N., Zimmermann M., Pils D., Mildner M., Petrasi Z., Petnehazy O., et al. Long-acting beneficial effect of percutaneously intramyocardially delivered secretome of apoptotic peripheral blood cells on porcine chronic ischemic left ventricular dysfunction. Biomaterials 2014, 35:3541-3550. 10.1016/j.biomaterials.2013.12.071.
208. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307. 10.1038/nature10144.
209. Segers V.F.M., Lee R.T. Protein therapeutics for cardiac regeneration after myocardial infarction. J. Cardiovasc. Transl. Res. 2010, 3:469-477. 10.1007/s12265-010-9207-5.
210. Segers V.F.M., Tokunou T., Higgins L.J., MacGillivray C., Gannon J., Lee R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692. 10.1161/circulationaha.107.718718.
211. Ziegler M., Elvers M., Baumer Y., Leder C., Ochmann C., Schoenberger T., et al. The bispecific SDF1-GPVI fusion protein preserves myocardial function after transient ischemia in mice. Circulation 2012, 125:685-696. 10.1161/circulationaha.111.070508.
212. Penn M.S., Mendelsohn F.O., Schaer G.L., Sherman W., Farr M., Pastore J., et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ. Res. 2013, 112:816-825. 10.1161/circresaha.111.300440.
213. Jabbour A., Hayward C.S., Keogh A.M., Kotlyar E., McCrohon J.A., England J.F., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail. 2011, 13:83-92. 10.1093/eurjhf/hfq152.
214. Kuhn B., del Monte F., Hajjar R.J., Chang Y.-S., Lebeche D., Arab S., et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med. 2007, 13:962-969. 10.1038/nm1619.
215. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 2000, 106:1511-1519. 10.1172/jci10226.
216. Urbanek K., Rota M., Cascapera S., Bearzi C., Nascimbene A., De Angelis A., et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res. 2005, 97:663-673. 10.1161/01.res.0000183733.53101.11.
217. Biomedica Corp Angion Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack 2012.
218. Torella D., Rota M., Nurzynska D., Musso E., Monsen A., Shiraishi I., et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. 2004, 94:514-524. 10.1161/01.res.0000117306.10142.50.
219. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
220. O'Sullivan J.F., Leblond A.-L., Kelly G., Kumar A.H.S., Metharom P., Büneker C.K., et al. Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circ. Cardiovasc. Interv. 2011, 4:327-335. 10.1161/CIRCINTERVENTIONS.110.960765.
221. Davis M.E., Hsieh P.C.H., Takahashi T., Song Q., Zhang S.G., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8155-8160. 10.1073/pnas.0602877103.
222. Chang M.-Y., Yang Y.-J., Chang C.-H., Tang A.C.L., Liao W.-Y., Cheng F.-Y., et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Control. Release 2013, 170:287-294. 10.1016/j.jconrel.2013.04.022.
223. Formiga F.R., Pelacho B., Garbayo E., Imbuluzqueta I., Diaz-Herraez P., Abizanda G., et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. J. Control. Release 2014, 173:132-139. 10.1016/j.jconrel.2013.10.034.
224. Johnson N.R., Wang Y. Controlled delivery of sonic hedgehog morphogen and its potential for cardiac repair. PLoS One 2013, 8. (e63075). 10.1371/journal.pone.0063075.
225. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Pepinsky R.B., et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 2001, 7:706-711. 10.1038/89083.
226. Fujita M., Ishihara M., Morimoto Y., Simizu M., Saito Y., Yura H., et al. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J. Surg. Res. 2005, 126:27-33. 10.1016/j.jss.2004.12.025.
227. Wu J., Zeng F., Huang X.-P., Chung J.C.Y., Konecny F., Weisel R.D., et al. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials 2011, 32:579-586. 10.1016/j.biomaterials.2010.08.098.
228. Bastings M.M.C., Koudstaal S., Kieltyka R.E., Nakano Y., Pape A.C.H., Feyen D.A.M., et al. A fast pH-switchable and self-healing supramolecular hydrogel carrier for guided, local catheter injection in the infarcted myocardium. Adv. Healthc. Mater. 2014, 3:70-78. 10.1002/adhm.201300076.
229. Ellison G.M., Torella D., Dellegrottaglie S., Perez-Martinez C., Perez de Prado A., Vicinanza C., et al. Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J. Am. Coll. Cardiol. 2011, 58:977-986. 10.1016/j.jacc.2011.05.013.
230. Song M., Jang H., Lee J., Kim J.H., Kim S.H., Sun K., et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP. Biomaterials 2014, 35:2436-2445. 10.1016/j.biomaterials.2013.12.011.
231. Ghadge S.K., Muhlstedt S., Ozcelik C., Bader M. SDF-1alpha as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther. 2011, 129:97-108. 10.1016/j.pharmthera.2010.09.011.
232. Abdel-Latif A., Bolli R., Zuba-Surma E.K., Tleyjeh I.M., Hornung C.A., Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am. Heart J. 2008, 156:216-226. 10.1016/j.ahj.2008.03.024.
233. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578. 10.1016/j.biomaterials.2010.08.097.
234. Banquet S., Gomez E., Nicol L., Edwards-Levy F., Henry J.P., Cao R., et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124:1059-1069. 10.1161/circulationaha.110.010264.
235. Projahn D., Simsekyilmaz S., Singh S., Kanzler I., Kramp B.K., Langer M., et al. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction. J. Cell. Mol. Med. 2014, n/a-n/a. 10.1111/jcmm.12225.
236. Yoon J., Min B.G., Kim Y.-H., Shim W.J., Ro Y.M., Lim D.-S. Differentiation, engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol. 2005, 60:277-284.
237. Ebelt H., Hillebrand I., Arlt S., Zhang Y., Kostin S., Neuhaus H., et al. Treatment with bone morphogenetic protein 2 limits infarct size after myocardial infarction in mice. Shock 2013, 39:353-360. 10.1097/SHK.0b013e318289728a.
238. Duan J., Gherghe C., Liu D., Hamlett E., Srikantha L., Rodgers L., et al. Wnt1/βcatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012, 31:429-442. 10.1038/emboj.2011.418.
239. Deb A. Cell-cell interaction in the heart via Wnt/β-catenin pathway after cardiac injury. Cardiovasc. Res. 2014, 102:214-223. 10.1093/cvr/cvu054.
240. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 2007, 28:2018-2027. 10.1093/eurheartj/ehm177.
241. Kawachi K., Iso Y., Sato T., Wakabayashi K., Kobayashi Y., Takeyama Y., et al. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 2012, 27:79-88. 10.1007/s00380-011-0197-2.
242. Sanchis-Gomar F., Garcia-Gimenez J.L., Pareja-Galeano H., Romagnoli M., Perez-Quilis C., Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int. J. Cardiol. 2014, 171:116-125. 10.1016/j.ijcard.2013.12.011.
243. Roubille F., Prunier F., Barrère-Lemaire S., Leclercq F., Piot C., Kritikou E.a, et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc. Drugs Ther. 2013, 27:315-331.
244. Brudno Y., Ennett-Shepard A.B., Chen R.R., Aizenberg M., Mooney D.J. Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials 2013, 34:9201-9209. (S0142-9612(13)00938-1 [pii]). 10.1016/j.biomaterials.2013.08.007.
245. Saif J., Schwarz T.M., Chau D.Y., Henstock J., Sami P., Leicht S.F., et al. Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1897-1904. (ATVBAHA.110.207928 [pii]). 10.1161/ATVBAHA.110.207928.
246. Dvir T., Kedem A., Ruvinov E., Levy O., Freeman I., Landa N., et al. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc Natl Acad Sci U S A 2009, 106:14990-14995. (0812242106 [pii]). 10.1073/pnas.0812242106.
247. Padin-Iruegas M.E., Misao Y., Davis M.E., Segers V.F., Esposito G., Tokunou T., et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009, 120:876-887. (CIRCULATIONAHA.109.852285 [pii]). 10.1161/CIRCULATIONAHA.109.852285.
248. Takehara N., Tsutsumi Y., Tateishi K., Ogata T., Tanaka H., Ueyama T., et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol. 2008, 52:1858-1865. (S0735-1097(08)03105-7 [pii]). 10.1016/j.jacc.2008.06.052.
249. Yacoub M.H., Terrovitis J. CADUCEUS, SCIPIO, ALCADIA: cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving. Glob. Cardiol. Sci. Pract. 2013, 2013:5-8. (gcsp.2013.3 [pii]). 10.5339/gcsp.2013.3.
250. Kubota Y., Miyagawa S., Fukushima S., Saito A., Watabe H., Daimon T., et al. Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. J. Thorac. Cardiovasc. Surg. 2014, 147:1081-1087. (S0022-5223(13)00600-4 [pii]). 10.1016/j.jtcvs.2013.05.035.
251. Shafy A., Fink T., Zachar V., Lila N., Carpentier A., Chachques J.C. Development of cardiac support bioprostheses for ventricular restoration and myocardial regeneration. Eur. J. Cardiothorac. Surg. 2013, 43:1211-1219. 10.1093/ejcts/ezs480.
252. Assmus B., Walter D.H., Seeger F.H., Leistner D.M., Steiner J., Ziegler I., et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013, 309:1622-1631. 10.1001/jama.2013.3527.
253. Chachques J.C. Development of bioartificial myocardium using stem cells and nanobiotechnology templates. Cardiol. Res. Pract. 2010, 2011:806795. 10.4061/2011/806795.
254. US Food and Drug Administration http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordination/ucm2018184.htm.
255. Sherman W., Martens T.P., Viles-Gonzalez J.F., Siminiak T. Catheter-based delivery of cells to the heart. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3(Suppl. 1):S57-S64. 10.1038/ncpcardio0446.
256. O'Cearbhaill E.D., Ng K.S., Karp J.M. Emerging medical devices for minimally invasive cell therapy. Mayo Clin. Proc. 2014, 89:259-273. 10.1016/j.mayocp.2013.10.020.
257. Chachques J.C., Azarine A., Mousseaux E., El Serafi M., Cortes-Morichetti M., Carpentier A.F. MRI evaluation of local myocardial treatments: epicardial versus endocardial (Cell-Fix catheter) injections. J. Interv. Cardiol. 2007, 20:188-196. 10.1111/j.1540-8183.2007.00255.x.
258. Hou D., Youssef E.A.-S., Brinton T.J., Zhang P., Rogers P., Price E.T., et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005, 112:I150-I156. 10.1161/CIRCULATIONAHA.104.526749.
259. Behfar A., Latere J.-P., Bartunek J., Homsy C., Daro D., Crespo-Diaz R.J., et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ. Cardiovasc. Interv. 2013, 6:710-718. 10.1161/CIRCINTERVENTIONS.112.000422.
260. Anastasiadis K., Antonitsis P., Argiriadou H., Koliakos G., Doumas A., Khayat A., et al. Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J. Transl. Med. 2011, 9:12. 10.1186/1479-5876-9-12.
261. Miyagawa S., Matsumiya G., Funatsu T., Yoshitatsu M., Sekiya N., Fukui S., et al. Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: report of a case. Surg. Today 2009, 39:133-136. 10.1007/s00595-008-3803-x.
262. Gojo S., Kyo S., Nishimura S., Komiyama N., Kawai N., Bessho M., et al. Cardiac resurrection after bone-marrow-derived mononuclear cell transplantation during left ventricular assist device support. Ann. Thorac. Surg. 2007, 83:661-662. 10.1016/j.athoracsur.2006.06.074.
263. Nasseri B.A., Kukucka M., Dandel M., Knosalla C., Potapov E., Lehmkuhl H.B., et al. Intramyocardial delivery of bone marrow mononuclear cells and mechanical assist device implantation in patients with end-stage cardiomyopathy. Cell Transplant. 2007, 16:941-949.